Corbus Pharmaceuticals Holdings, Inc. Interest Expense Nonoperating
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Interest Expense Nonoperating of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-03-09
- Corbus Pharmaceuticals Holdings, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest expense nonoperating for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest expense nonoperating for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. interest expense nonoperating for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. interest expense nonoperating for fiscal 2024 was $1.87M, a 51.48% decline from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. interest expense nonoperating for fiscal 2023 was $3.86M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-03-09 | $381.00K derived: sum of 4 quarters · filed 2026-03-09 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-09 | $381.00K derived: sum of 3 quarters · filed 2026-03-09 | $1.03M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $381.00K derived: sum of 2 quarters · filed 2026-03-09 | $1.03M derived: sum of 3 quarters · filed 2026-03-09 | $1.87M 10-K · filed 2026-03-09 |
| 2024-09-30 | $381.00K 10-Q · filed 2025-11-12 | $1.03M derived: sum of 2 quarters · filed 2025-11-12 | $1.87M 10-Q · filed 2025-11-12 | $2.80M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $652.00K 10-Q · filed 2025-08-05 | $1.49M 10-Q · filed 2025-08-05 | $2.42M derived: sum of 3 quarters · filed 2025-08-05 | $3.40M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $839.00K 10-Q · filed 2025-05-06 | $1.77M derived: sum of 2 quarters · filed 2025-05-06 | $2.75M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $930.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.91M derived: sum of 2 quarters · filed 2025-03-11 | $3.86M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $980.00K 10-Q · filed 2024-11-07 | $2.93M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |